butabarbital decreases consequences of sufentanil SL by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Intently. Coadministration of CYP3A4 inducers may lower sufentanil concentrations and efficacy, perhaps precipitating withdrawal syndrome in patients that have formulated Actual physical dependence to sufentanil. Discontinuation of concomitantly made use of CYP3A4 inducers may perhaps improve sufentanil plasma concentration.

butabarbital will lessen the level or outcome of glecaprevir/pibrentasvir by impacting hepatic/intestinal enzyme CYP3A4 metabolism.

butabarbital will lessen the extent or effect of ramelteon by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Minimal/Importance Unknown.

butabarbital will lower the extent or effect of pitolisant by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Keep an eye on Intently. Pitolisant publicity is lessened by fifty% if coadministered with robust CYP3A4 inducers.

butabarbital will reduce the extent or result of maraviroc by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Check.

butabarbital will minimize the level or impact of prednisone by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Watch.

butabarbital will decrease the level or influence of parecoxib by influencing hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.

butabarbital will lessen the extent or outcome of ixabepilone by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Keep an eye on.

butabarbital will reduce the extent or impact of cilostazol by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Watch.

butabarbital will decrease the level or outcome of buprenorphine subdermal implant by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Watch Closely. Observe sufferers already on buprenorphine subdermal implant who involve newly-initiated treatment method with CYP3A4 inducer for signals and signs of withdrawal.

butabarbital will decrease the extent or impact of paclitaxel protein sure by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Importance Unidentified.

butabarbital will lessen the extent or impact of nateglinide by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Check.

Its intermediate duration of action gives butabarbital an abuse prospective a little decreased than secobarbital. Butabarbital could be hydrolyzed to valnoctamide.[four] Stereoisomeres of check here butabarbital

butabarbital will decrease the extent or outcome of fludrocortisone by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Watch.